Stroke Congress Research Articles

The 6Th World Stroke Congress, Vienna, 24–27 September, 2008

The 6Th World Stroke Congress, Vienna, 24–27 September, 2008

World Stroke Day 2008

See World Stroke Day Proclamation Appendix, pages 2409–2420. World Stroke Day is a day with a message for every day: “Stroke is a treatable and preventable catastrophe.” This year and every subsequent year it will be on October 29th. The theme for this year is “Little strokes, big trouble”. During the World Stroke Congress in Vancouver in 2004, a working group was organized to develop a global agenda for stroke. This agenda was subsequently incorporated into a World Stroke Proclamation launched in Cape Town on October 26, 2006 (supplemental video, available online at http://stroke.ahajournals.org). The 2007 World Stroke Day theme was “Stroke is a treatable and preventable catastrophe and hypertension is its most common and treatable factor”. This year the stroke global agenda will be highlighted at the forthcoming 6th World …

Advances in Critical Care and Emergency Medicine 2007

The emergency room is the front line in the battle against stroke. In 2007 the results of 2 phase III international stroke trials were announced: DIAS-2 evaluated IV recombinant tissue plasminogen activator (rtPA) within an expanded time window based on the demonstration of MR perfusion-diffusion mismatch, and FAST was designed to confirm the clinical benefits of early hemostatic therapy with recombinant activated factor VII (rFVIIa) for intracerebral hemorrhage (ICH). These trials promised to usher in a new era of therapy for thousands of acute stroke victims in our emergency departments. Unfortunately, both trials were negative. On the brighter side, however, a meta-analysis of 3 European hemicraniectomy trials for middle cerebral artery (MCA) infarction showed a powerful mortality reduction. These studies have established hemicraniectomy with duroplasty as the treatment of choice for younger patients (<60 years) admitted to intensive care with medically refractory edema and intracranial pressure related to MCA infarction. ICH is widely recognized as the deadliest and least treatable form of stroke. Thus, it was with great anticipation that the results of the FAST trial were announced at the European Stroke Congress in Glasgow in the spring of 2007. FAST was designed to confirm the strikingly positive results of an earlier phase IIB trial investigating the effects of rFVIIa on hematoma expansion in the acute phase of ICH. In addition to an approximate 50% reduction in ICH volume growth, 3 doses of rFVIIa (40, 80, and 160 μg/kg) were collectively associated with a statistically significant 38% mortality reduction, as well as improved functional outcomes according to the modified Rankin scale (mRS).1 In FAST, the experiment was repeated with the exact same inclusion and exclusion criteria (no upper limit on baseline ICH volume), time window (up to 4 hours), and clinical outcome measure (the frequency of death or severe …

An overview of stroke management from the 6th World Stroke Congress

An overview of stroke management from the 6th World Stroke Congress

An overview of stroke management from the 6th World Stroke Congress

An overview of stroke management from the 6th World Stroke Congress

Emerging Therapies for Cerebrovascular Disorders

Emerging Therapies for Cerebrovascular Disorders

Critical Care and Emergency Medicine Neurology in Stroke

Dramatic changes have occurred in the area of critical care and emergency stroke treatments of intracerebral hemorrhage (ICH). New data from three sponsored clinical trials: STICH (British National Health System-Medical Research Council), NOVO Seven (Novonordisk), and intraventricular hemorrhage (IVH) clot lysis (FDA Orphan Drug Program)1 were presented at the 29th International Stroke Meeting2 and the World Stroke Congress. Several avenues of approach to the problem of ICH are opening. Although the data from these trials are now under peer review, the initial presentations have demonstrated several principles that seem clear. First, craniotomy (though not better than initial medical management) is safe and not worse than initial medical management. Second, deterioration occurs frequently (≈25% of the time) in the initial days after ICH. Deterioration was treated with surgery. Third, a strategy of emergent clot stabilization is safe and shows trends toward efficacy in the NOVO Seven dose finding study.2 Finally, catheter-assisted removal of blood clot from the obstructed ventricular system in IVH can be accomplished safely with low dose recombinant tissue plasminogen activator (rtPA).3 These trial results suggest that the basic elements of aneurysm care are now being applied to ICH care: emergent stabilization of the bleeding site, followed by removal of blood and management of cranial vault mechanics. Data are now beginning to support that applying these principles leads to improvement in mortality and morbidity. We hope that the robustness of the peer-reviewed data continues to point to the value of emergent intervention for the ICH patient. New sponsored trials have already started: CLEAR IVH, a phase IIb dose optimization trial directed at finding the best dose of rtPA to rapidly remove blood from the ventricles (FDA Orphan drug program)4; MISTIE, an NIH sponsored phase II safety study of minimally invasive surgery plus …

5th World Stroke Congress

5th World Stroke Congress

5 th World Stroke Congress

5 th World Stroke Congress

5th World Stroke Congress

5th World Stroke Congress

Announcement 5th World Stroke Congress

Announcement 5th World Stroke Congress

Announcement: 5th World Stroke Congress

Announcement: 5th World Stroke Congress

Conference report. World Stroke Congress, 25-29 November 2000, Melbourne, Australia.

Conference report. World Stroke Congress, 25-29 November 2000, Melbourne, Australia.

Abstracts From the 4th World Stroke Congress

Abstracts From the 4th World Stroke Congress

The Society for Vascular Surgery: Then and now

The Society for Vascular Surgery: Then and now

Book reviews

A Research Manual for the Performance Course in Speech. By Paul D. Brandes and Theodore J. Walwik. New York: Harper & Row, 1967; pp. xi + 340; paperback, $3.95. Proceedings of the National Stroke Congress. By Ralph E. deForst, M.D. (ed.). Springfield: Charles C. Thomas, 1966; pp. vi + 234; $7.50. The Stuttering Child—in the School and in the Home. By R. Corbin Pennington and Elizabeth James. Danville, Illinois: Interstate Printers and Publishers, Inc., 1967; pp. 37; paperbound, $.60. Championship Debating, Volume II. Edited by Russel R. Windes and Arthur N. Kruger. Portland, Maine: J. Weston Walch, 1967; pp. v + 226; paperbound, $3.50.

Book Review: Prevention and Treatment of Stroke: Proceedings of the National Stroke Congress

Book Review: Prevention and Treatment of Stroke: Proceedings of the National Stroke Congress

Books Received

Journal Article Books Received Get access Proceedings of the National Stroke Congress. Edited by Ralph E. De Forest. Charles C Thomas, Publisher, Springfield, Illinois, 1966. Cloth, illus., 234 pp., $7.50. Physical Therapy, Volume 46, Issue 9, September 1966, Page 1018, https://doi.org/10.1093/ptj/46.9.1018b Published: 01 September 1966

Proceedings of the National Stroke Congress. Rehabilitation—Management—Prevention.

Proceedings of the National Stroke Congress. Rehabilitation—Management—Prevention.

First Stroke Congress Scheduled

Journal Article First Stroke Congress Scheduled Get access Physical Therapy, Volume 44, Issue 10, October 1964, Page 930, https://doi.org/10.1093/ptj/44.10.930 Published: 01 October 1964